🇺🇸 FDA
Patent

US 9782416

Pharmaceutical formulations of potassium ATP channel openers and uses thereof

granted A61KA61K31/549A61K31/655

Quick answer

US patent 9782416 (Pharmaceutical formulations of potassium ATP channel openers and uses thereof) held by ESSENTIALIS, INC. expires Mon Oct 05 2037 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
ESSENTIALIS, INC.
Grant date
Tue Oct 10 2017 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon Oct 05 2037 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
10
CPC classes
A61K, A61K31/549, A61K31/655, A61K9/0004, A61K9/2054